Study shows how TRK-fusion lung cancer escapes LOXO-101, offering new treatment strategies
A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101, a kinase inhibitor of the TRK-fusion ...
Apr 18, 2016
0
4